Introduction
Anti-HIV ribozymes expressed retrovirally in hematopoietic stem cells or CD4 + T cells have been proposed for gene therapy of HIV infection. [1] [2] [3] [4] [5] Ribozymes are RNA molecules that possess the ability to specifically cleave RNA target sequences. 6 During this decade hammerhead and hairpin ribozymes against a wide variety of sequences in the HIV genome, eg against Pol, 7 Tat, 8 Rev 9 or the 5Ј-LTR 10 have been developed. In vitro, retrovirally expressed anti-HIV ribozymes were able to reduce HIVreplication by 1-4 logs for several weeks. These promising results led to the application of retrovirally expressed anti-HIV ribozymes in clinical trials. 11 Apart from a sufficient inhibition of HIV replication, a selective advantage of cells expressing anti-HIV ribozymes is a prerequisite for the success of a ribozymebased gene therapy of HIV infection. In particular, the expression of anti-HIV ribozymes in CD4 + T cells can only be effective if the genetically modified cells possess an advantage in comparison to unprotected cells, eg by inhibition of the cytopathic effect of the virus. Considering the high turn-over of CD4 + T cells 12 in HIV infected individuals this could theoretically result in a progressively increasing ratio of protected CD4 + T cells ultimately ture was monitored by flow cytometry. Twenty-one days after HIV infection the proportion of ribozyme expressing CD4 + T cells was 2.6 times higher in comparison to cells with the control vector. CD4
+ T cells with a strong ribozyme expression conferred a 7.4-fold selective advantage at day 21 and a 11.7-fold at day 28. For Hut78 cells a selective advantage was detected exclusively for strongly ribozyme expressing cells. As a mechanism underlying the selective advantage an inhibition of HIV induced apoptosis was shown. These results demonstrate that anti-HIV ribozymes are able to confer a selective survival advantage and indicate that the protective effect is dependent on the amount of ribozyme expression. Gene Therapy (2000) 7, 408-416. leading to the generation of a ribozyme expressing HIVresistant T cell system.
Although anti-HIV ribozymes are able to inhibit in vitro HIV replication effectively, so far there have been no in vivo or in vitro studies demonstrating a selective advantage of ribozyme expressing cells. Therefore, the specific aims of the study were: (1) to generate an anti-HIV ribozyme encoding retroviral vector mediating a highly effective inhibition of HIV replication; (2) the development of an assay to detect a selective advantage for cells expressing an anti-HIV ribozyme; and (3) the demonstration of a selective advantage, ie an increase of survival of CD4 + T cells after HIV challenge. As an anti-HIV ribozyme we used the sequence of the previously described hairpin ribozyme directed against the 5Ј LTR, which was demonstrated as a highly effective inhibitor of HIV-1 replication. 2 The ribozyme sequence was cloned into a Moloney-based vector directly upstream of the reporter, the gene of the intracellularly truncated low affinity nerve growth factor receptor (LNGF-R⌬). 13 As confirmed by semi-quantitative RT-PCR the amount of ribozyme transcripts could be easily assessed by detection of LNGF-R⌬ molecules at the cell surface. This vector was applied to an assay, which was based on the principle that the selective pressure of HIV should give the ribozyme expressing cells a selective advantage when competing with wild-type cells. Using this assay, we detected an increased proportion of cells protected by a ribozyme after a challenge with HIV.
Results

Ribozyme expression
For inhibition of HIV-1 replication the sequence of the previously described hairpin ribozyme directed against the second GUC triplet in the HIV-1 HXB2 LTR was inserted into a retroviral vector solely expressing the LNGF-R⌬ as a reporter. 2 The ribozyme cDNA was inserted directly upstream of the reporter gene. To confirm the specificity of the ribozyme effect the control vectors LCo and LHPLtrIA were designed. LCo is a vector without a ribozyme coding sequence. LHPLtrIA codes for an inactive non-cleaving hairpin ribozyme directed against the same sequence as LHPLtr. 2 The vectors are depicted in Figure 1 .
Replication-incompetent retroviral vectors were produced by Phoenix and FlyRD18 packaging cell lines. Hut78 were transduced with Phoenix and primary CD4 + T cells with FlyRD18 virus supernatants. The transduction efficiency in Hut78 cells was 5-15% and in CD4
+ T cells 20-44% as determined by flow cytometry (data not shown).
Correlation between cell surface LNGF-R⌬ and ribozyme mRNA expression A potential protective effect of anti-HIV ribozymes is likely to be dose dependent. To determine whether the level of ribozyme expression could be assessed approximately by FACS analysis of the density of LNGF-R⌬ surface expression transduced cells were separated into three cell fractions on the basis of high (HE), medium (ME) and low (LE) intensity staining with an anti-LNGF-R⌬ mAb. When the amount of ribozyme mRNA transcripts in these three fractions was analyzed by semiquantitative RT-PCR a strict correlation was observed (R 2 = 0.94, Figure 2a ). The level of RNA ribozyme transcripts was 6.4 times higher and the average surface LNGF-R⌬ expression was seven times stronger in the HE cell fraction as compared with the LE fraction. Between LE and ME cells these factors were 2 (RNA) and 2.2 (surface LNGF-R⌬), respectively. To demonstrate further that the expression level of the retroviral vector is stable and not influenced, eg by cell cycle or functional activity, the average level of LNGF-R⌬ expression per cell in the sorted cell fractions was reanalyzed after 3 months of culture. As shown in Figure  2b the average LNGF-R⌬ expression levels were essentially identical.
Selective advantage of ribozyme expressing cells
An assay system to examine the selective advantage conferred by an anti-HIV ribozyme under the selective press- In eight independent experiments the average RSA for all ribozyme expressing primary CD4 + T cells 21 days after HIV-1 infection (MOI = 0.01) was 2.6 ± 0.4. At day 28 it was 2.0 ± 0.3 ( Figure 4b ). When only the highly ribozyme expressing CD4 + T cells were analyzed (ϾFl-1 channel 200 (HE)), the RSA was 7.4 ± 1.3 at day 21 and 11.7 ± 4.6 at day 28 ( Figure 4c ). For cells infected with a higher initial HIV-1 dose (MOI = 0.1) no selective advantage was demonstrated during the whole observation period (data not shown). Primary CD4 + T cells transduced with the control vector (LCo) without a ribozyme coding sequence conferred no selective advantage. To confirm the specificity of the ribozyme effect the LHPLtrIA vector which has only an antisense effect was examined. This vector did not confer any selective advantage either. Table 1 
Inhibition of apoptosis by anti-HIV ribozymes
To elucidate the mechanism of the selective advantage the rate of apoptotic cell death was determined by flow cytometry by 7-AAD staining ( Figure 5a ). LHPLtr or LCo transduced Hut78 were purified by MACS and subsequently HIV-1 infected (MOI = 0.01). Figure 5b shows the rate of apoptotic cell death 9 days after HIV-1 infection. The average percentage of apoptotic cells was 16.9 ± 3.5 for LHPLtr expressing and 24.4 ± 0.5 for LCo transduced cells. When subtracting the percentage of apoptotic cells without HIV challenge (7.5%) the rate of HIV-induced apoptotic cell death was inhibited by 44%. Since the selective advantage was demonstrated to be dependent on the level of ribozyme expression the rate of inhibition of apoptosis was analyzed separately for cells with a strong LNGF-R⌬ expression (ϾFl-1 channel 300 (HE)). 24.1 ± 0.9% of the highly control vector expressing cells versus 9.8 ± 4.7% of the highly LHPLtr expressing cells were apoptotic. After subtraction of the non-HIV-related apoptosis the reduction of the rate of apoptotic cells was 71%.
Inhibition of HIV-1 replication HIV-1 replication by LHPLtr or LCo transduced Hut78 cells was analyzed to demonstrate the antiviral effect of the applied ribozyme. LHPLtr or LCo transduced LNGF-R⌬ expressing Hut78 cells were isolated by immunomagnetic cell sorting followed by HIV-1 IIIb infection (MOI = 0.01). In Figure 6a the kinetics of HIV-1 replication (p24 concentration) is depicted. During the first 3 weeks HIV replication was efficiently reduced by 3-4 logs. In two of the four experiments the inhibition of HIV replication was reduced after day 16. Between day 23 and day 30 the ribozyme conferred inhibition of HIV replication failed. In the remaining experiments HIV replication was suppressed by at least 4 logs until day 37 and day 44, respectively. At the end of the observation at day 51 in the third experiment HIV replication reached the control level while in the last experiment HIV replication was still inhibited by approximately 3 logs.
The same experiments were repeated with highly LHPLtr or LCo expressing Hut78 cells (HE). After transduction highly LNGF-R⌬ expressing cells were isolated by fluorescence activated cell sorting followed by exposure to HIV-1 (MOI = 0.01). In three of three experiments with the strongly anti-HIV ribozyme-positive cells the HIV replication was inhibited by at least 4 logs until the end of the observation at day 49 (Figure 6b ).
Figure 4 (a) Representative FACS analysis out of eight independent experiments of LNGF-R⌬ expression by a mixture of LHPLtr expressing and unmodified primary CD4 + T cells 21 days after infection with HIV-1 (MOI = 0.01). The percentage of all LNGF-R⌬ and of highly LNGF-R⌬ (FL-1 channel Ͼ200) expressing cells is indicated. As controls the FACS analysis of LCo (vector without a ribozyme coding sequence) and
Discussion
Retrovirally expressed anti-HIV ribozymes have been demonstrated to be efficient inhibitors of HIV-1 replication in vitro. The previously described and well characterized ribozyme targeting the second GUC triplet in the 5ЈLTR of HIV-1 HXB2 was utilized, since it has been shown to inhibit HIV replication efficiently.
2 Our assay to detect However, for the highly LNGF-R⌬-positive subset of cells the RSA was 7.4 ± 1.3 at day 21 and 11.7 ± 4.6 at day 28, ie the proportion of CD4 + T cells with a strong ribozyme expression was almost 12 times higher after a selective pressure of 4 weeks.
Using the control vector (LCo) expressing cells the results for the RSA were confirmed to be always approximately 1 (no selective advantage) as a proof that the selective advantage was not conferred by the vector. To confirm the specificity of the ribozyme effect a vector (LHPLtrIA) expressing an inactive ribozyme which has been described before by Ojwang et al 2 was applied. This ribozyme has no cleavage activity and can therefore act only as an antisense molecule. Since LHPLtrIA transduced CD4
+ T cells had no selective advantage the RSA conferred by LHPLtr was proven to be a ribozyme and not an antisense effect.
The RSA of LHPLtr transduced primary CD4 + T cells already peaked 21 days after HIV-1 infection followed by no further increase. Although this plateau may indicate the end of a selective advantage it may also be caused by the artificial culture conditions with a strong mitogenic stimulation resulting in a maximal induction of HIV-1 replication.
The investigation of the whole population of LHPLtr transduced Hut78 cells revealed no selective advantage. Only when focusing on the subset of Hut78 cells with a high level of LNGF-R⌬, ie ribozyme expression, was a RSA of approximately 2 detected ( Table 1 ). The RSA was correlated positively with the amount of ribozyme expression. Despite using a ribozyme with an efficient inhibition of HIV replication (Figure 6 ), the selective advantage was limited even for those Hut78 cells with the strongest ribozyme expression.
The mechanism underlying the selective advantage appears to involve a reduced rate of apoptotic cell death. The HIV-induced rate of apoptotic cells was reduced by 44% in ribozyme expressing Hut78 cells. In accordance with the correlation between the level of ribozyme expression and the RSA the inhibition of apoptotic cell death was even higher in strongly ribozyme expressing cells (71%). Although a selective advantage could not be demonstrated for the whole population of ribozyme expressing Hut78 cells a reduction of apoptotic cell death was observed. This discrepancy might be due to the early development of resistance of Hut78 cells towards HIVinduced apoptosis. A reduction of apoptotic cell death could only be observed in the first 10 days after HIV inoculation. Then the HIV-induced rate of apoptotic cells decreased spontaneously and a benefit for the ribozyme expressing Hut78 cells in terms of inhibition of apoptosis was no longer observable (data not shown). The development of resistance towards HIV-induced apoptosis might also explain the limited selective advantage even for those Hut78 cells with the strongest ribozyme expression. Despite the significant RSA a reduction of the HIVinduced apoptotic cell death in ribozyme expressing primary CD4
+ T cells could not be demonstrated (data not shown). This might be due to the already mentioned strong mitogenic stimulation with IL-2 and anti-CD3 resulting in a high rate of spontaneously apoptotic cells.
Our results serve as a proof of principle for gene therapy with anti-HIV ribozyme expressing CD4 + T cells. However, even with primary CD4 + T cells a relevant selective advantage could be observed only in conjunction with an extremely high level of ribozyme expression, which was almost 10-fold above the average expression level. The limited in vitro selective advantage for the whole population of ribozyme expressing cells is consistent with the inability, at least to date, to detect a selective advantage in a clinical setting. Our results therefore suggest that a much stronger average retroviral expression of anti-HIV ribozymes may be required for a clinical application.
To exclude the possibility that an insufficient inhibition of HIV-1 replication by our vector system and by the utilized ribozyme underlies the limited selective advantage especially of anti-HIV ribozyme expressing Hut78 cells, HIV-1 replication was monitored in Hut78 culture supernatants by p24 ELISA. Compared with earlier published data the inhibition of HIV-1 replication was effective even with the bulk culture of all ribozyme expressing cells. In the first 3 weeks HIV-1 replication was inhibited by 3 logs in four independent experiments. After 30 days, HIV replication reached the level of the control vector transduced cells in two of four experiments. In the two remaining experiments a prolonged inhibition of HIV replication was evident until partial or complete termination of the inhibition occurred in the final week of the observation (day 51). When the same experiments were performed with highly ribozyme expressing Hut78 cells, HIV-1 replication was inhibited almost completely in all experiments until the end of the monitoring after 49 days.
The frequently reported early failure of ribozyme conferred inhibition of HIV replication is usually attributed to either a silencing of the vector or the development of HIV escape mutants. For our vector system a silencing could be excluded as the transduced Hut78 cells remained LNGF-R⌬ positive for as long as 8 months until the end of their observation (data not shown). Moreover, the vector was still expressed even after the inhibition of HIV replication had ceased. Mutations in the HIV-1 genome as a reason for the failure of anti-HIV ribozymes have been suggested repeatedly, but have not yet been demonstrated. 8, 19 Our results clearly show that both the selective advantage and the inhibition of HIV-1 replication are dependent on the amount of ribozyme expression. Furthermore, the occurrence of a selective advantage of ribozyme expressing CD4
+ T cells can be demonstrated at an initial HIV-1 MOI of 0.01, but not after an initial HIV-1 inoculation with a MOI of 0.1. Thus, we suggest that the proportion between the amount of HIV-1 RNA and the amount of ribozyme transcripts is important for success or failure of a ribozyme-based inhibition of HIV-1 replication. If the amount of HIV-1 RNA in a cell becomes too high the ribozymes may be unable to control HIV-1 replication and thereby lose their ability to provide a selective advantage by inhibition of apoptosis.
In conclusion, a selective advantage was demonstrated for anti-HIV ribozyme expressing cells. This selective advantage is dependent on the amount of ribozyme expression; only CD4 + T cells with a strong ribozyme expression substantially benefit from the ribozymes. These results provide evidence that the degree of ribozyme expression achieved by conventional Moloney-based retroviral vectors as used in ongoing clinical trials, are not sufficient to provide a relevant selective advantage and to prevent the early failure of HIV inhibition. Thus, superior vectors enabling a significantly higher ribozyme expression level are required. Finally, we suggest that the ability to confer a selective advantage is an appropriate assay system for testing the antiviral activity of a ribozyme or a ribozyme expression system.
Materials and methods
Ribozyme and vector design
To express the ribozyme sequence a LN-based retroviral vector was used. Instead of the neomycin resistance gene the LNGF-R⌬ (intracellularly truncated low affinity nerve growth factor receptor) gene was inserted as a reporter. The resulting vector served as a control and was therefore designated as LCo (this vector was kindly provided by S Seeber, Boehringer Mannheim, Penzberg, Germany). The ribozyme sequence was inserted in the LCo vector upstream of the LNGF-R⌬ gene. After EcoRI restriction and generation of blunt-ends by the Klenow fragment a XhoI linker was inserted. After XhoI restriction a linker containing a NotI restriction site was inserted. The orientation of the linker was confirmed by DNA sequencing (Perkin Elmer, Weiterstadt, Germany).
The cDNA of the hairpin ribozyme against the second GUC triplet in the 5ЈLTR of HIV-1 strain HXB2 which was originally developed by Ojwang et al 2 was synthesized as two complementary synthetic oligonucleotides (Interactiva, Ulm, Germany). After XhoI and NotI restriction of the vector the ribozyme oligonucleotide which contained a SpeI restriction site was inserted. Ligation of the ribozyme sequence was confirmed by SpeI digestion. The vector containing the ribozyme sequence was defined as LHPLtr. In addition to LCo a further control vector was designed to confirm the specificity of the ribozyme effect. In the vector LHPLtrIA the cDNA of an inactive ribozyme (HPLtrIA) targeted against the same target sequence as LHPLtr was inserted. As described by Ojwang et al 2 a AAA triplet in the second loop of the hairpin ribozyme was replaced by CGT. The structure of the vectors is depicted in Figure 1 
Production of retroviral vectors
For transduction of the T lymphoblastic cell line Hut78, the retroviral vectors were transiently transfected into the amphotropic Phoenix packaging cell line (kindly provided by G Nolan, Stanford University, Stanford, CA, USA) by the calcium-phosphate method. 20 For transduction of primary CD4 + T cells high-titer virus supernatants were produced by the packaging cell line FlyRD18. 21 Twenty g of plasmid DNA and 2 g of the plasmid pSV40neo expressing the neomycin resistance gene were co-transfected into FlyRD18 cells by calcium-phosphate precipitation. To generate stable packaging cell lines FlyRD18 cells were selected for neomycin resistance for 2 weeks at 37°C and 5% CO 2 in DMEM supplemented with 1 mm sodium pyruvate, 100 units/ml penicillin, 100 g/ml streptomycin, 5% sodium bicarbonate, 10% heat inactivated fetal calf serum (Serva, Heidelberg, Germany), and 1 mg/ml G418 (Gibco, Karlsruhe, Germany).
Cell isolation and culture PBMC from healthy adult volunteers were isolated by Ficoll-Histopaque (Seromed, Berlin, Germany) density gradient centrifugation after informed consent. Primary CD4 + T cells were purified by immunomagnetic cell sorting using a MACS cell sorting device (Miltenyi Biotec, Bergisch Gladbach, Germany) in accordance with the manufacturer's recommendations. CD4 + T cells were cultured in RPMI-1640 (Gibco) supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, 10 m Hepes, 10% heat inactivated FCS (Serva), 200 units/ml IL-2 (Genzyme, Rü sselsheim, Germany), 100 ng/ml OKT3 (Ortho, Neckarsulm, Germany), and 10 ng/ml IL-1␤ (Genzyme) at 37°C. Hut78 cells were cultured in RPMI-1640 supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, 0.1 mm sodium pyruvate, and 15% heat inactivated FCS (Serva).
Transduction
For transduction 1 × 10 6 Hut78 cells were suspended in 3 ml Phoenix culture supernatant supplemented with 4 g/ml protamin sulfate (Gibco) in 12 ml tissue culture tubes (Greiner, Nü rtingen, Germany). After a 90 min 700 g spinoculation at 32°C cells were incubated for another 2.5 h at 37°C in 5% CO 2 . Then supernatants were removed and the cells were cultured as described above.
Before transduction CD4 + T cells were pre-cultured as described above for 48 h. For transduction 5 × 10 5 CD4
+ T cells were suspended in 3 ml FlyRD-18 culture supernatant supplemented with 4 g/ml protamin sulfate, 200 units/ml IL-2, 100 ng/ml OKT3, and 10 ng/ml IL-1␤ in 12 ml tissue culture tubes. The transduction was performed as described for Hut78 cells. Twenty-four hours after the first spinoculation the transduction was repeated. Transduction efficiency was analyzed 48 h after the last transduction.
Analysis and purification of transduced cells LNGF-R⌬ expression was analyzed by flow cytometry on a FACScan (Becton Dickinson, Heidelberg, Germany). Cells were stained with anti-LNGF-R mAb (Boehringer Mannheim, Germany) followed by a second step incubation with FITC-conjugated goat-f(ab) 2 anti-mouse-Ig Ab (Southern Biotechnology, Birmingham, AL, USA). Transduced Hut78 cells expressing LNGF-R⌬ were isolated by immunomagnetic cell sorting using a MACS cell sorting device (Miltenyi Biotec) or by fluorescence activated cell sorting on a FACSCalibur (Becton Dickinson).
The purity (Ͼ99%) of the sorted LNGF-R⌬ + cells was confirmed by flow cytometry. In addition to the whole LNGF-R⌬ + fraction cells were sorted with respect to the density of LNGF-R⌬ expression as high (HE, FL-1 channel Ͼ300), medium (ME, FL-1 channel 80-300) and low (LE, FL-1 channel 30-80) LNGF-R⌬ expressing cells.
RNA extraction and PCR analysis
Ribozyme expression was quantified by RT-PCR. Total RNA obtained from Hut78 cells was isolated according to the method of Chomczynski and Sacchi. 22 cDNA was generated by reverse transcription of total RNA. After denaturation of RNA for 5 min at 70°C cDNA was synthesized at 42°C for 1 h in a final volume of 20 l using 1 l random hexadeoxynucleotide primers (500 ng/ml), 10 l RNA, 1 l Superscript reverse transcriptase (200 U/l), 1 l 10 mm dNTP-mix, 4 l 5 × RT-buffer, 2 l 0.1 m dithiotretiol (all from Gibco BRL, Karlsruhe, Germany), and 1 l RNAguard (34 U/l, Pharmacia, Freiburg, Germany).
␤-Actin PCR was performed as an external standard to control variability of yield and quality of mRNA. PCR was carried out in a final volume of 50 l containing the cDNA obtained from the RNA of 5 × 10 5 cells, 0.4 l recombinant Taq-Polymerase (5 U/l, Gibco), 5 l 10 × PCR buffer (Gibco), 1 l 10 mm dNTP-mix (Gibco), 1.5 l 50 mm MgCl 2 and 1 l of 5Ј and 3Ј primers (10 pmol/l). The following primers spanning 548 bp were used: 5Ј-GTG GGG CGC CCC AGG CAC CA-3Ј, 5Ј-CTC CTT AAT GTC ACG CAC GAT TTC-3Ј. The PCR samples were heated to 94°C for 3 min. Subsequent cycles were conducted in three temperature steps: 30 s at 94°C, 45 s at 60°C and 30 s at 72°C. After 24 cycles 20 l of each PCR product were loaded on a 2% agarose gel stained with ethidium bromide. A molecular mass standard (low DNA mass ladder, Gibco) was added to determine size and amount of ␤-actin PCR product. The mean density of the bands of the molecular mass standard and of each ␤-actin PCR product were quantified using the Gel Doc 1000 documentation system and Molecular Analyst software (Biorad, Hercules, CA, USA).
For semiquantitative detection of the ribozyme expression primers binding within the ribozyme sequence and within the LNGF-R⌬ gene and spanning 850 bp were synthesized (5Ј-GGC CGC ACT AGT ACA CAA CAA GAA-3Ј; 5Ј-CAC CAC ACC TGC CAC CGT GCT GGC TAT GAG-3Ј). The PCR was performed in a final volume of 50 l containing cDNA, 0.5 l of 5Ј and 3Ј primer stocks (10 pmol/l), 0.5 l recombinant Taq (5 U/l), 5 l 10 × PCR-buffer, 1 l 10 mm dNTP-mix, 3 l 50 mm MgCl 2 , and 10% dimethylsulfoxide (DMSO). The amount of added cDNA was normalized according to the result of the ␤-actin PCR. The PCR samples were heated to 94°C for 3 min. Subsequent cycles were conducted in three temperature steps: 45 s at 94°C, 45 s at 66°C and 1 min at 72°C. After 30 cycles the PCR product was analyzed on an ethidium bromide-stained 2% agarose gel. The mean density of PCR products was analyzed by Molecular Analyst software (Biorad).
HIV-1 infection Hut78 and primary CD4
+ T cells were infected with virus supernatants derived from chronically HIV-1 IIIb infected H9 cells. The titer of HIV supernatants was determined by endpoint titration on C8166 cells as Gene Therapy described before. 23 Cells were infected with a MOI of 0.01 or 0.1. After a 3 h incubation cells were washed three times and resuspended in RPMI-1640 medium at a concentration of 1 × 10 5 cells/ml in 12-well tissue culture plates (Costar, Cambridge, MA, USA). Every other day, half of the cell suspension was removed and replaced by fresh culture media supplemented as described above. Weekly, the number of viable cells was determined by trypan blue exclusion and culture supernatants were collected. HIV replication was monitored by determination of the p24 concentration (p24 ELISA, Coulter, Krefeld, Germany) in the culture supernatants.
Selective advantage assay
To determine whether the retrovirally expressed anti-HIV ribozyme conferred a selective advantage after exposure to HIV-1, Hut78 and CD4
+ T cells transduced with LHPLtr, LCo or LHPLtrIA were mixed with unmodified cells. The percentage of LNGF-R⌬-positive cells was adjusted between 2 and 6. These cell mixtures were then infected with HIV-1 as described above with a MOI of 0.01 and 0.1 and mock. Seven, 14, 21 and 28 days after HIV-1 challenge cell aliquots were harvested and analyzed for the percentage and density of LNGF-R⌬ expression by FACS. At different density levels of LNGF-R⌬ expression (Hut78: all LNGF-R⌬ + cells, the upper half (Fl-1 channel Ͼ180) and high LNGF-R⌬ expression (Fl-1 channel Ͼ300); primary CD4 + T cells: all LNGF-R⌬ + cells and high LNGF-R⌬ expression (Fl-1 channel Ͼ200) ) the percentage of LNGF-R⌬-positive cells with a LNGF-R⌬ expression which was stronger than these thresholds was determined. To quantify the selective advantage at different density levels of LNGF-R⌬ expression a ratio of the percentage of LNGF-R⌬-positive cells after HIV infection and without HIV inoculation was defined as the relative selective advantage (RSA).
To elucidate the mechanism of a selective advantage the percentage of apoptotic cells was determined by flow cytometry after a 20 min pre-incubation with 7-amino actinomycin D (7-AAD, 20 g/ml) as described by Schmid et al. 24 The rate of apoptotic cells was determined for all LNGF-R⌬ and for highly LNGF-R⌬-positive cells.
